Cullinan Oncology, Inc. (CGEM) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Cullinan Oncology, Inc. (CGEM) Bundle
Discover the true value of Cullinan Oncology, Inc. (CGEM) with our advanced DCF Calculator! Adjust essential assumptions, explore various scenarios, and evaluate how different factors affect Cullinan Oncology's valuation – all within a single Excel template.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | 18.9 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | -100 | 0 | -25 | -25 | -25 | -25 | -25 |
EBITDA | -22.2 | -60.3 | -67.9 | 151.4 | -190.3 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | -358.45 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
Depreciation | .1 | .1 | .1 | .1 | .3 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 0.27979 | 100 | 100 | 80.06 | 80.06 | 80.06 | 80.06 | 80.06 |
EBIT | -22.3 | -60.3 | -68.0 | 151.3 | -190.6 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | -358.73 | 100 | 100 | 60 | 60 | 60 | 60 | 60 |
Total Cash | 98.6 | 210.2 | 430.9 | 550.1 | 467.1 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 0 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 0 | 100 | 100 | 80 | 80 | 80 | 80 | 80 |
Accounts Payable | .9 | 9.7 | 3.2 | 2.7 | 2.5 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 16.73 | 100 | 100 | 83.35 | 83.35 | 83.35 | 83.35 | 83.35 |
Capital Expenditure | .0 | .0 | -.6 | -1.1 | -.2 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | -3.11 | 100 | 100 | -0.6221 | -0.6221 | -0.6221 | -0.6221 | -0.6221 |
Tax Rate, % | 9.49 | 9.49 | 9.49 | 9.49 | 9.49 | 9.49 | 9.49 | 9.49 | 9.49 | 9.49 |
EBITAT | -20.6 | -51.6 | -65.5 | 111.2 | -172.6 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -19.6 | -42.8 | -72.5 | 109.7 | -172.6 | -2.5 | .0 | .0 | .0 | .0 |
WACC, % | 5.38 | 5.38 | 5.39 | 5.38 | 5.38 | 5.38 | 5.38 | 5.38 | 5.38 | 5.38 |
PV UFCF | ||||||||||
SUM PV UFCF | -2.4 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -2 | |||||||||
Net Debt | -95 | |||||||||
Equity Value | 92 | |||||||||
Diluted Shares Outstanding, MM | 42 | |||||||||
Equity Value Per Share | 2.23 |
What You Will Receive
- Pre-Loaded Financial Model: Cullinan Oncology's actual data provides accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
- Real-Time Calculations: Automatic updates allow you to view results instantly as you make adjustments.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.
Key Features
- Comprehensive Financial Data: Gain access to reliable pre-loaded historical figures and future forecasts for Cullinan Oncology, Inc. (CGEM).
- Adjustable Forecast Parameters: Modify yellow-highlighted fields such as WACC, growth rates, and profit margins to suit your analysis.
- Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Intuitive charts and summaries that make it easy to interpret your valuation outcomes.
- Designed for All Users: A straightforward, user-friendly layout tailored for investors, CFOs, and consultants alike.
How It Works
- Download the Template: Gain immediate access to the Excel-based CGEM DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Cullinan Oncology’s intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential valuation shifts.
- Analyze and Decide: Leverage the results to inform your investment or financial analysis.
Why Choose This Calculator for Cullinan Oncology, Inc. (CGEM)?
- Comprehensive Tool: Integrates DCF, WACC, and financial ratio analyses tailored for CGEM.
- Customizable Inputs: Modify yellow-highlighted cells to explore different investment scenarios.
- Detailed Insights: Automatically computes Cullinan Oncology’s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide a solid foundation for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focused on CGEM.
Who Should Use This Product?
- Investors: Accurately assess Cullinan Oncology’s fair value before making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to CGEM.
- Consultants: Efficiently modify the template for valuation reports tailored to clients in the biotech sector.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading pharmaceutical companies.
- Educators: Implement it as a teaching resource to illustrate valuation techniques in the healthcare industry.
What the Template Contains
- Historical Data: Includes Cullinan Oncology’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Cullinan Oncology’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Cullinan Oncology’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.